Arginine

Generic Name: Arginine

Brand Names: Aminosyn II 7 %, Sulfite-free, Aminosyn-PF 7%, Clinimix 2.75/5, Clinimix E 2.75/5, Clinisol 15, Freamine 6.9, Freamine III 10, Hepatamine 8, Olimel, Periolimel, Plenamine, Premasol, Primene, Procalamine 3, Prosol, R-gene, Travasol 10, Trophamine 10 %

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₄N_₄O_₂

CAS Number: 74-79-3

Unique Ingredient Identifier: 94ZLA3W45F

Background: An essential amino acid that is physiologically active in the L-form.

Indication: Used for nutritional supplementation, also for treating dietary shortage or imbalance.

Associated Conditions: Acromegaly, Craniopharyngioma, Disorders of urea cycle metabolism, Gigantism, Hyperammonaemia, Hypophysectomy, Kidney Damage, Panhypopituitarism, Pituitary Dwarfism, Pituitary Neoplasms, Pituitary trauma, Problems of growth and stature

Associated Therapies: Nutritional supplementation, Amino acid supplementation

Clinical Trials

Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE)

Not Applicable

Not yet recruiting

Conditions: Overt Hepatic Encephalopathy

Interventions: Drug: Human albumin infusion at a modified dosage
Drug: Human albumin infusion at a routine dosage
Drug: Lactulose
Drug: Rifaximin
Drug: Ornithine Aspartate
Drug: Branched-Chain Amino Acids
Drug: Arginine
Device: plasma exchange

First Posted Date: 2024-07-03

Last Posted Date: 2024-07-08

Lead Sponsor: General Hospital of Shenyang Military Region

Target Recruit Count: 174

Registration Number: NCT06483737

Locations: 🇨🇳
Department of Gastroenterology, General Hospital of Northern Theater Command (formerly called General Hospital of Shenyang Military Area), Shenyang, Liaoning, China

Study of Felzartamab in Healthy Adult Subjects

Phase 1

Recruiting

Conditions: Healthy

Interventions: Drug: T
Drug: R

First Posted Date: 2024-02-29

Last Posted Date: 2024-04-15

Lead Sponsor: TJ Biopharma Co., Ltd.

Target Recruit Count: 60

Registration Number: NCT06285201

Locations: 🇨🇳
The First Hospital of Jilin University, Jilin, Changchun, China

Improving Quality of Life and Daily Life Activities With Bioarginine in Patients With COPD

Not Applicable

Recruiting

Conditions: COPD
Dyspnea
Argininemia

Interventions: Drug: Placebo
Drug: Arginine

First Posted Date: 2022-06-09

Last Posted Date: 2024-01-09

Lead Sponsor: University of Milan

Target Recruit Count: 152

Registration Number: NCT05412160

Locations: 🇮🇹
L. Sacco Hospital, Milan, Italy

Compare the Pharmacokinetics and Safety of CKD-391 With Co-administration of D086 and D337

Phase 1

Completed

Conditions: Hyperlipidemias

Interventions: Drug: T
Drug: R

First Posted Date: 2019-01-04

Last Posted Date: 2019-01-07

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 45

Registration Number: NCT03793985

Locations: 🇰🇷
INHA University Hospital, Incheon, Korea, Republic of

Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease

Phase 1

Recruiting

Conditions: Sickle Cell Disease

Interventions: Drug: Arginine (Loading)
Drug: Arginine
Drug: Arginine (Continuous)

First Posted Date: 2015-05-19

Last Posted Date: 2024-06-14

Lead Sponsor: Emory University

Target Recruit Count: 21

Registration Number: NCT02447874

Locations: 🇺🇸
Children's Healthcare fo Atlanta at Hughes Spalding, Atlanta, Georgia, United States
🇺🇸
Children's Healthcare of Atlanta at Egleston, Atlanta, Georgia, United States

Ghrelin and Beta Cell Function in Diabetes

Phase 1

Withdrawn

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Synthetic human AG
Drug: Arginine
Drug: 0.9% saline solution

First Posted Date: 2015-05-12

Last Posted Date: 2018-04-02

Lead Sponsor: Jenny Tong, MD, MPH

Registration Number: NCT02440061

Locations: 🇺🇸
Duke Center For Living, Durham, North Carolina, United States

Arginine Therapy in Sickle Cell Disease-VOC Clinical Trial

Phase 2

Completed

Conditions: Vaso-occlusive Pain Episodes

Interventions: Drug: Arginine
Drug: Placebo

First Posted Date: 2013-02-22

Last Posted Date: 2013-07-31

Lead Sponsor: UCSF Benioff Children's Hospital Oakland

Target Recruit Count: 56

Registration Number: NCT01796678

Locations: 🇺🇸
Childrens Hospital Research Center Oakland, Oakland, California, United States

N-Acetylcysteine and Arginine Administration in Diabetic Patients

Phase 4

Terminated

Conditions: Type 2 Diabetes Mellitus
Hypertension

Interventions: Drug: Placebo
Drug: Arginine
Drug: Acetylcysteine

First Posted Date: 2007-12-07

Last Posted Date: 2007-12-07

Lead Sponsor: University of Turin, Italy

Target Recruit Count: 24

Registration Number: NCT00569465

Locations: 🇮🇹
"San Giovanni Battista" Hospital of Turin, Turin, Italy

Effectiveness of Arginine as a Treatment for Sickle Cell Anemia

Phase 2

Completed

Conditions: Anemia, Sickle Cell

Interventions: Drug: Placebo
Drug: Arginine

First Posted Date: 2007-08-08

Last Posted Date: 2017-03-29

Lead Sponsor: UCSF Benioff Children's Hospital Oakland

Target Recruit Count: 128

Registration Number: NCT00513617

Locations: 🇺🇸
University of Mississippi Medical Center (Pediatric), Jackson, Mississippi, United States
🇺🇸
Children's Medical Center of Dallas, Dallas, Texas, United States
🇺🇸
Kosair Children's Hospital, Louisville, Kentucky, United States

and more 14 locations

Arginine and Buphenyl in Patients With Argininosuccinic Aciduria (ASA), a Urea Cycle Disorder

Phase 2

Completed

Conditions: Argininosuccinic Aciduria
Amino Acid Metabolism, Inborn Errors
Urea Cycle Disorders

Interventions: Drug: Sodium Phenylbutyrate
Drug: Arginine

First Posted Date: 2006-06-28

Last Posted Date: 2018-01-31

Lead Sponsor: Brendan Lee

Target Recruit Count: 12

Registration Number: NCT00345605

Locations: 🇺🇸
Baylor College of Medicine, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy